Can we effectively manage chronic kidney disease with a precision-based pharmacotherapy plan? Where are we?
F Locatelli, E Paoletti, M Ravera… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction In recent years, thanks to significant advances in basic science and
biotechnologies, nephrology has witnessed a deeper understanding of the mechanisms …
biotechnologies, nephrology has witnessed a deeper understanding of the mechanisms …
A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat
F Locatelli, M Ravera, C Esposito, G Grandaliano… - Journal of …, 2024 - Springer
Anemia is a frequent and early chronic kidney disease (CKD) complication. Its management
is currently based on oral or intravenous iron supplements, erythropoiesis-stimulating …
is currently based on oral or intravenous iron supplements, erythropoiesis-stimulating …
Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a document by the European Renal Best Practice board of the European …
S Stoumpos, K Crowe, P Sarafidis… - Nephrology Dialysis …, 2024 - academic.oup.com
Anaemia is a common complication of chronic kidney disease (CKD) and is associated with
poor long-term outcomes and quality of life. The use of supplemental iron, erythropoiesis …
poor long-term outcomes and quality of life. The use of supplemental iron, erythropoiesis …
[HTML][HTML] Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials
T Hamano, Y Yamaguchi, K Goto, S Martin… - Advances in …, 2024 - Springer
Introduction Risk factors for thromboembolic events in patients with dialysis-dependent
chronic kidney disease (CKD) receiving roxadustat are unknown. Iron deficiency has been …
chronic kidney disease (CKD) receiving roxadustat are unknown. Iron deficiency has been …
[HTML][HTML] Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney …
F Locatelli, L Del Vecchio, C Esposito, L Gesualdo… - Journal of …, 2024 - Springer
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new drugs developed
for the treatment of anemia associated with chronic kidney disease (CKD). This class of …
for the treatment of anemia associated with chronic kidney disease (CKD). This class of …
Hypoxia inducible factor prolyl hydroxylase inhibitors: what a meta-analysis could tell us
F Locatelli, C Zoccali - Clinical Kidney Journal, 2024 - academic.oup.com
Meta-analyses offer an estimate of the overall effect size and help address the inconsistency
in findings across studies. The risk is the overemphasis on statistical significance while …
in findings across studies. The risk is the overemphasis on statistical significance while …
Resistance to erythropoiesis stimulating agents in a dialysis patient after kidney graft failure
S Borrelli, C Garofalo, F Marzano, PT Ambrosino… - Journal of …, 2024 - Springer
A 41-year-old woman was referred to our clinic because of advanced kidney failure due to a
non-functioning graft 15 years after kidney transplantation. A left mid-arm arteriovenous …
non-functioning graft 15 years after kidney transplantation. A left mid-arm arteriovenous …
[HTML][HTML] MANEJO DE LA FERROPENIA
MDELOSAE DE, LA ERITROPOYESIS - nefrologiaaldia.org
La prescripción de hierro, junto con los AEE y los inhibidores de las prolil-hidroxilasas del
factor inducible por hipoxia (PHI-HIF)(estabilizadores del HIF), forma parte de los tres …
factor inducible por hipoxia (PHI-HIF)(estabilizadores del HIF), forma parte de los tres …